The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic
The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic
Dosyalar
Tarih
2022-01-01
Yazarlar
Ekizoglu, Esme
Gezegen, Hasim
Yalinay Dikmen, Pinar
Orhan, Elif Kocasoy
Ertas, Mustafa
Baykan, Betul
Süreli Yayın başlığı
Süreli Yayın ISSN
Cilt Başlığı
Yayınevi
SAGE PUBLICATIONS LTD
Dergi Adı
CEPHALALGIA
Özet
Introduction Headache is a frequent adverse event after viral vaccines. We aimed to investigate the frequency and clinical associations of COVID-19 vaccine-related headache. Methods The characteristics, associations of this headache, main comorbidities, headache history following the influenza vaccine and during COVID-19 were investigated using a web-based questionnaire. Results A total of 1819 healthcare personnel (mean age: 44.4 +/- 13.4 years, 1222 females), vaccinated with inactivated virus, contributed to the survey
209 (11.4\%) had been infected with COVID-19. A total of 556 participants (30.6\%) reported headache with significant female dominance (36.1\% vs. 19.3\%), 1.8 +/- 3.5 (median: 1
IQR: 0-2) days following vaccination. One hundred and forty-four participants (25.9\%) experienced headache lasting >= 3 days. Headache was mostly bilateral without accompanying phenomena, less severe, and shorter than COVID-19-related headache. The presence of primary headaches and migraine were significantly associated with COVID-19 vaccine-related headache (ORs = 2.16 {[}95\% CI 1.74-2.68] and 1.65 {[}1.24-2.19], respectively). Headache during COVID-19 or following influenza vaccine also showed significant association with headache following COVID-19 vaccine (OR = 4.3 {[}95\% CI 1.82-10.2] and OR = 4.84 {[}95\% CI 2.84-8.23], respectively). Only thyroid diseases showed a significant association (OR = 1.54 {[}95\% CI 1.15-2.08]) with vaccine-related headache among the common comorbidities. Conclusion Headache is observed in 30.6\% of the healthcare workers following COVID-19 vaccine and mostly experienced by females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.
209 (11.4\%) had been infected with COVID-19. A total of 556 participants (30.6\%) reported headache with significant female dominance (36.1\% vs. 19.3\%), 1.8 +/- 3.5 (median: 1
IQR: 0-2) days following vaccination. One hundred and forty-four participants (25.9\%) experienced headache lasting >= 3 days. Headache was mostly bilateral without accompanying phenomena, less severe, and shorter than COVID-19-related headache. The presence of primary headaches and migraine were significantly associated with COVID-19 vaccine-related headache (ORs = 2.16 {[}95\% CI 1.74-2.68] and 1.65 {[}1.24-2.19], respectively). Headache during COVID-19 or following influenza vaccine also showed significant association with headache following COVID-19 vaccine (OR = 4.3 {[}95\% CI 1.82-10.2] and OR = 4.84 {[}95\% CI 2.84-8.23], respectively). Only thyroid diseases showed a significant association (OR = 1.54 {[}95\% CI 1.15-2.08]) with vaccine-related headache among the common comorbidities. Conclusion Headache is observed in 30.6\% of the healthcare workers following COVID-19 vaccine and mostly experienced by females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.
Açıklama
Anahtar kelimeler
COVID-19 vaccine, vaccination, vaccine, headache, adverse event